China's palmoplantar pustulosis (PPP) market is witnessing robust growth, primarily driven by the rising incidence of this dermatological disorder. PPP, a chronic autoimmune skin condition characterized by painful pustules on the palms and soles, has led to increased demand for effective treatments. This growing patient population has propelled pharmaceutical companies to develop innovative therapies and medications targeting PPP. Consequently, the market is expanding as these new treatments gain acceptance, creating a favorable environment for research, development, and commercialization of solutions tailored to the unique needs of PPP patients.
Access Full Report @ https://www.databridgemarketresearch.com/reports/china-palmoplantar-pustulosis-ppp-market
Data Bridge Market Research analyses that China Palmoplantar Pustulosis (PPP) Market is expected to grow at a CAGR of 5.60% in the forecast period of 2023 to 2030 and is expected to reach USD 126.8 million by 2030 from USD 82.01 million in 2022. China's aging population is increasingly vulnerable to palmoplantar pustulosis (PPP), resulting in a larger patient base. As individuals age, their risk of developing PPP rises, necessitating enhanced healthcare services and treatments to cater to this growing demographic affected by the condition.
Key Findings of the Study
Patient demand is expected to drive the market's growth rate
Patient demand is pivotal in the China palmoplantar pustulosis (PPP) market. Affected individuals seek advanced, innovative therapies to manage their condition effectively. This growing demand not only addresses the immediate needs of patients but also propels the market's evolution, encouraging continuous research and development in the quest for better PPP treatments.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Type A and Type B), Severity (Mild-Moderate and Moderate-Severe), diagnosis (Laboratory Tests and Skin Biopsy) Treatment (Emollients, Topical Steroids, Coal tar, Phototherapy) Population Type (Children and Adults), Route Of Administration (Oral, Topical and Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy).
|
|
Market Players Covered
|
Novartis AG (Switzerland), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), AstraZeneca (U.K.), GSK plc (U.K.), Merck & Co., Inc. (U.S.), Amgen inc. (U.S.), AnGes, Inc. (Japan), Johnson & Johnson Private Limited (U.S.), AbbVie Inc. (U.S.), Perrigo Company plc (Ireland), WOCKHARDT (India), Bausch Health Companies Inc. (Canada), Viatris Inc. (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Xiromed (U.S.) and Encube Ethicals Private Limited (U.S.).
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The China palmoplantar pustulosis (PPP) market is segmented on the basis of disease type, severity, diagnosis, treatment, population type, route of administration, end user and distribution channel.
- On the basis of disease type, the China palmoplantar pustulosis (PPP) market is classified into type A and type B
- On the basis of severity, the China palmoplantar pustulosis (PPP) market is classified into mild-moderate and moderate-severe
- On the basis of diagnosis, the China palmoplantar pustulosis (PPP) market is classified into laboratory tests and skin biopsy
- On the basis of treatment, the China palmoplantar pustulosis (PPP) market is classified into emollients, topical steroids, coal tar, and phototherapy
- On the basis of population type, the China palmoplantar pustulosis (PPP) market is classified into children and adults
- On the basis of route of administration, the China palmoplantar pustulosis (PPP) market is classified into oral, topical and parenteral
- On the basis of end user, the China palmoplantar pustulosis (PPP) market is classified into hospitals, homecare, specialtycClinics, and others.
- On the basis of distribution channel, the China palmoplantar pustulosis (PPP) market is classified into hospital pharmacy, online pharmacy, and retail pharmacy.
Major Players
Data Bridge Market Research recognizes the following companies as the major China palmoplantar pustulosis (PPP) market players in China palmoplantar pustulosis (PPP) market are AnGes, Inc. (Japan), Johnson & Johnson Private Limited (U.S.), AbbVie Inc. (U.S.), Perrigo Company plc (Ireland), WOCKHARDT (India), Bausch Health Companies Inc. (Canada), Viatris Inc. (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Xiromed (U.S.) and Encube Ethicals Private Limited (U.S.).
Market Developments
- In February 2023, Chinese pharmaceutical giant Sinopharm announced a strategic collaboration with Nanomed Therapeutics, a leader in dermatological research. This partnership aims to develop innovative palmoplantar pustulosis (PPP) treatments tailored to the Chinese market. Sinopharm's extensive reach and Nanomed's expertise promise significant advancements in PPP therapeutics for Chinese patients
- In September 2022, Shanghai Biotech announced a strategic collaboration with Pfizer Inc. to develop and commercialize a groundbreaking PPP treatment. This partnership leverages Pfizer's research expertise and Shanghai Biotech's local market insights to address the unmet needs of PPP patients in China, promising innovative solutions in the near future
- In March 2022, two major pharmaceutical companies, Sinopharm and Shanghai Pharmaceuticals, announced a strategic collaboration to advance research and development in the China palmoplantar pustulosis (PPP) market. This partnership aims to jointly create innovative therapies for PPP patients, leveraging Sinopharm's expertise in biologics and Shanghai Pharmaceuticals' extensive distribution network, promising enhanced treatment options for this challenging skin condition
- In June 2021, Beijing Pharma Corporation and Jiangsu Biotech announced a strategic collaboration in the China Palmoplantar Pustulosis (PPP) Market. This partnership aims to co-develop innovative therapies for PPP, leveraging Beijing Pharma's market expertise and Jiangsu Biotech's research capabilities. The collaboration seeks to address the unmet medical needs of PPP patients and strengthen their position in this evolving market
For more detailed information about the China palmoplantar pustulosis (PPP) market report, click here – https://www.databridgemarketresearch.com/reports/china-palmoplantar-pustulosis-ppp-market
